Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea.
Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea.
Korean J Radiol. 2018 Mar-Apr;19(2):352-357. doi: 10.3348/kjr.2018.19.2.352. Epub 2018 Feb 22.
This study assessed the risk of acute allergic-like reactions (AARs) after extravascular administration of iodinated contrast media (ICM) in at-risk patients compared with that after intravascular ICM administration.
From July 2012 to January 2016, 264 patients with a history of moderate or severe reactions to ICM, with re-exposure to ICM intravascularly or extravascularly were included. The incidence of recurrent AARs after ICM re-exposure were assessed according to the administration routes by reviewing electronic medical records and comparison between the two routes.
Among 264 patients, 244 patients had been subsequently exposed to ICM intravascularly, 7 patients via an extravascular route and 13 patients with dual re-exposure. Of 257 patients with intravascular ICM re-exposure, 87 (33.9%) had mild to severe recurrent AARs and 143 (19.5%) cases of recurrent AARs occurred among 733 cases of intravascular ICM re-exposure on a case-by-case basis. However, there was no case of recurrent ARR after extravascular administration of ICM in 20 patients (45 cases) with ICM administrated extravascularly.
For high-risk patients with a history of moderate or severe reactions to ICM, AARs upon extravascular administration of ICM are significantly infrequent compared with intravascular ICM administration.
本研究评估了有中度或重度碘造影剂(ICM)反应史的高危患者接受血管外与血管内 ICM 给药后发生急性过敏样反应(AAR)的风险。
2012 年 7 月至 2016 年 1 月,共纳入 264 例有 ICM 中度或重度反应史、再次接受 ICM 血管内或血管外给药的患者。通过回顾电子病历和比较两种给药途径,评估 ICM 再暴露后 AAR 复发的发生率。
在 264 例患者中,244 例患者随后接受了血管内 ICM 暴露,7 例患者通过血管外途径,13 例患者同时接受了两种途径。在 257 例接受血管内 ICM 再暴露的患者中,87 例(33.9%)出现轻度至重度复发性 AAR,143 例(19.5%)在 733 例血管内 ICM 再暴露中出现复发性 AAR。然而,在 20 例(45 例)接受血管外 ICM 给药的患者中,无一例发生血管外 ICM 给药后复发性 AAR。
对于有中度或重度 ICM 反应史的高危患者,与血管内 ICM 给药相比,血管外 ICM 给药后发生 AAR 的情况明显较少。